Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper

Heparin, Baxter, the FDA and China

publication date: Mar 5, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

The FDA and Baxter International announced today that a heparin-like molecule found in Baxter’s supplies of heparin may be the culprit in the recent wave of heparin-caused side effects. Baxter, which produces half of the US supply of heparin, has recalled all of its heparin products. Between 5% and 20% of the raw material sampled seemed to be contaminated. The brouhaha has caused a call for more and better FDA inspections of foreign-sourced drugs and APIs, but that may be difficult to achieve.  More details...

Stock Symbol: (NYSE: BAX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events


BioPacific Conference 2012
June 2, 2012
California, USA

  China Forum 2012
  November 11, 2012
Hamburg, Germany

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners